Epilepsy Drug Dilantin May Speed Bone Loss
Study Shows Young Women Taking Dilantin May Be at Long-Term Risk for Fractures
WebMD News Archive
April 30, 2008 -- Young women
taking the common epilepsy drug Dilantin may risk bone loss and fracture with
A new study shows young women taking phenytoin (also commonly known as
Dilantin) for one year lost 2.6% of the bone density in the femoral neck -- the
upper part of the thigh bone near the hip joint. It's a common and dangerous
site for fractures among the elderly.
Although previous studies have shown use of epilepsy drugs can have negative effects on bone mineral density
(BMD) and bone metabolism (how quickly old bone is turned over by new
bone), researchers say this is one of the first studies to look at the
long-term effect of individual epilepsy drugs on bone loss.
"This is a significant amount of bone loss and raises serious concerns
about the long-term effects of taking phenytoin in young women with
epilepsy," says researcher Alison M. Pack, MD, with Columbia University in
New York, in a news release. "This amount of bone loss, especially it if
continues over the long term, could put these women at increased risk of
fractures after menopause."
Checking for Bone Mineral Density
In the study, researchers followed 93 premenopausal women (age 18-40) taking
one of four different epilepsy drugs: carbamazepine (also known with brand
names Tegretol and Carbatrol), lamotrigine (Lamictal), valproate (Depakene), and Dilantin, for one
year. Bone mineral density of the spine and two areas of the hip (femoral neck
and total hip) were measured at the start and end of the study.
The results, published in Neurology, showed that women taking
Dilantin experienced an average of 2.6% bone loss in the femoral neck only. No
significant bone loss was found among those taking the other three epilepsy
Bone turnover markers were unchanged among the other groups, but women
taking Dilantin experienced a decline in at least one marker.
Researchers say the women in the study did not have other risk factors for
bone loss, were physically active, and reported high levels of calcium intake
(more than 1,000 milligrams a day), which raises concerns about using Dilantin
as a sole therapy for epilepsy.
Dilantin's Maker Responds
Dilantin is made by the drug
company Pfizer, which notes that Dilantin (phenytoin) was developed
in 1938 as the first modern anti-epileptic drug.
"Some drugs used to treat
epilepsy, including Dilantin, can result in osteomalacia (bone softening due to
defective bone demineralization). This effect appears to be greater in patients
taking multiple drugs, those with longer duration of epilepsy, and those taking
enzyme-inducing anti-epileptic medications," states Pfizer in an email
to WebMD, adding that osteomalacia is noted in the
"precautions" section of Dilantin's prescribing information.
"Epilepsy is a common chronic
neurological disorder that can have dire consequences if left
untreated," states Pfizer. "As with all medications, physicians
and patients should weigh the potential risks of treatment with Dilantin
against the benefits."
With additional reporting by